Complass – Navigate compliance Complass – Navigate compliance

Framework

Cybersecurity for medical devices (MDR/IVDR)

Connected medical devices and software as a medical device must be securely developed, documented and monitored in the field under the MDR and IVDR. Complass guides manufacturers and suppliers of the medical technology industry from the threat model to vulnerability reporting.

Still from the short video “Compliance management in 20 seconds”
Compliance management in 20 seconds Project, next step, checklist, Statement of Applicability, audit package. Beispieldaten der Demo-Firma.

What is Medical devices?

The Medical Devices Regulation (EU) 2017/745 (MDR) and the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 (IVDR) require software to be developed according to the state of the art, risk management to include information security and manufacturers to set out minimum requirements for hardware, IT networks and IT security measures. Guidance MDCG 2019-16 Rev. 1 explains what this means in practice.

Content as of:

Does it apply to me?

The requirements apply to manufacturers of medical devices and in vitro diagnostic medical devices that contain software or are software. Suppliers of electronics, embedded software, radio modules or contract manufacturing are affected indirectly: manufacturers pass the requirements on to them through the quality management system and contracts and expect, for example, an SBOM, a security data sheet and commitments on updates.

Medical devices are excluded from the Cyber Resilience Act. Components with digital elements that are also sold on their own or outside medical technology, however, generally fall under the CRA. Manufacturers of medical devices and in vitro diagnostic medical devices of medium size or larger can additionally fall under NIS2 (Annex 2 BSIG).

This overview does not replace legal advice. The legal or normative text is authoritative; in Complass you check applicability with guidance based on the references.

Legal basis

  • Art. 2 MDRArticle 2 MDR DefinitionsFor the purposes of this Regulation, the following definitions apply: (1) ‘medical device’ means any instrument, apparatus, appliance, software, implant, reagent, material or other article intended by the manufacturer to be used, alone or in combination, for human beings for one or more of the following specific medical purposes: - diagnosis, prevention, monitoring, prediction, prognosis, treatment or alleviation of …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 19.07.2026Open original (EUR-Lex – consolidated version of 19.07.2026) ↗Definitions, including medical device and accessory
  • Art. 10 MDRArticle 10 MDR General obligations of manufacturers1. When placing their devices on the market or putting them into service, manufacturers shall ensure that they have been designed and manufactured in accordance with the requirements of this Regulation. 2. Manufacturers shall establish, document, implement and maintain a system for risk management as described in Section 3 of Annex I. 3. Manufacturers shall conduct a clinical evaluation in accordance with the …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 19.07.2026Open original (EUR-Lex – consolidated version of 19.07.2026) ↗General obligations of manufacturers
  • Anhang I Abschn. 17.2 MDRAnnex I Section 17.2 MDRFor devices that incorporate software or for software that are devices in themselves, the software shall be developed and manufactured in accordance with the state of the art taking into account the principles of development life cycle, risk management, including information security, verification and validation.As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 19.07.2026Open original (EUR-Lex – consolidated version of 19.07.2026) ↗Software life cycle, risk management including information security
  • Anhang I Abschn. 17.4 MDRAnnex I Section 17.4 MDRManufacturers shall set out minimum requirements concerning hardware, IT networks characteristics and IT security measures, including protection against unauthorised access, necessary to run the software as intended.As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 19.07.2026Open original (EUR-Lex – consolidated version of 19.07.2026) ↗Minimum requirements for hardware, IT networks and IT security measures
  • Art. 83 MDRArticle 83 MDR Post-market surveillance system of the manufacturer1. For each device, manufacturers shall plan, establish, document, implement, maintain and update a post-market surveillance system in a manner that is proportionate to the risk class and appropriate for the type of device. That system shall be an integral part of the manufacturer's quality management system referred to in Article 10(9). 2. The post-market surveillance system shall be suited to actively and …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 19.07.2026Open original (EUR-Lex – consolidated version of 19.07.2026) ↗Post-market surveillance system
  • Art. 87 MDRArticle 87 MDR Reporting of serious incidents and field safety corrective actions1. Manufacturers of devices made available on the Union market, other than investigational devices, shall report, to the relevant competent authorities, in accordance with Articles 92(5) and (7), the following: - (a) any serious incident involving devices made available on the Union market, except expected side-effects which are clearly documented in the product information and quantified in the technical …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 19.07.2026Open original (EUR-Lex – consolidated version of 19.07.2026) ↗Reporting of serious incidents and field safety corrective actions
  • Anhang I Abschn. 16.2 IVDRAnnex I Section 16.2 IVDRFor devices that incorporate software or for software that are devices in themselves, the software shall be developed and manufactured in accordance with the state of the art taking into account the principles of development life cycle, risk management, including information security, verification and validation.As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 10.01.2025Open original (EUR-Lex – consolidated version of 10.01.2025) ↗Corresponding requirement for software of in vitro diagnostic medical devices
  • Art. 2 Abs. 2 CRAArticle 2 Cyber Resilience Act Scope1. This Regulation applies to products with digital elements made available on the market, the intended purpose or reasonably foreseeable use of which includes a direct or indirect logical or physical data connection to a device or network. 2. This Regulation does not apply to products with digital elements to which the following Union legal acts apply: - (a) Regulation (EU) 2017/745; - (b) Regulation (EU) 2017/746; …As of: 06.10.2026 · Source: EUR-Lex – OJ L 2024/2847, 20.11.2024, corrigenda incorporated: OJ L 2024/90780, 5.12.2024; OJ L 2025/90555, 2.7.2025; OJ L 2025/90828, 17.10.2025Open original (EUR-Lex – OJ L 2024/2847, 20.11.2024, corrigenda incorporated: OJ L 2024/90780, 5.12.2024; OJ L 2025/90555, 2.7.2025; OJ L 2025/90828, 17.10.2025) ↗Exclusion of medical devices from the Cyber Resilience Act

Key dates

  1. Date of application of the MDR · Art. 123(2) MDRArticle 123 MDR Entry into force and date of application1. This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union. 2. It shall apply from 26 May 2021 . 3. By way of derogation from paragraph 2: - (a) Articles 35 to 50 shall apply from 26 November 2017. However, from that date until 26 May 2021 , the obligations on notified bodies pursuant to Articles 35 to 50 shall apply only to those …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 19.07.2026Open original (EUR-Lex – consolidated version of 19.07.2026) ↗
  2. Date of application of the IVDR · Art. 113(2) IVDRArticle 113 IVDR Entry into force and date of application1. This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union. 2. It shall apply from 26 May 2022. 3. By way of derogation from paragraph 2: ————— - (b) Articles 31 to 46 and Article 96 shall apply from 26 November 2017. However, from that date until 26 May 2022 the obligations on notified bodies pursuant to Articles 31 to 46 shall …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 10.01.2025Open original (EUR-Lex – consolidated version of 10.01.2025) ↗
  3. MDR legacy devices: QMS in accordance with Art. 10(9) put in place and formal application lodged with a notified body (condition of the transitional period) · Art. 120(3c)(d) and (e) MDRArticle 120 MDR Transitional provisions1. From 26 May 2021 , any publication of a notification in respect of a notified body in accordance with Directives 90/385/EEC and 93/42/EEC shall become void. 2. Certificates issued by notified bodies in accordance with Directives 90/385/EEC and 93/42/EEC prior to 25 May 2017 shall remain valid until the end of the period indicated on the certificate, except for certificates issued in accordance with Annex 4 to …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 19.07.2026Open original (EUR-Lex – consolidated version of 19.07.2026) ↗
  4. MDR legacy devices: written agreement signed with the notified body (condition of the transitional period) · Art. 120(3c)(e) MDRArticle 120 MDR Transitional provisions1. From 26 May 2021 , any publication of a notification in respect of a notified body in accordance with Directives 90/385/EEC and 93/42/EEC shall become void. 2. Certificates issued by notified bodies in accordance with Directives 90/385/EEC and 93/42/EEC prior to 25 May 2017 shall remain valid until the end of the period indicated on the certificate, except for certificates issued in accordance with Annex 4 to …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 19.07.2026Open original (EUR-Lex – consolidated version of 19.07.2026) ↗
  5. Obligations relating to the first Eudamed modules (actors, UDI/devices, notified bodies and certificates, market surveillance) apply · Art. 123(3)(d) MDR in conjunction with Decision (EU) 2025/2371Article 123 MDR Entry into force and date of application1. This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union. 2. It shall apply from 26 May 2021 . 3. By way of derogation from paragraph 2: - (a) Articles 35 to 50 shall apply from 26 November 2017. However, from that date until 26 May 2021 , the obligations on notified bodies pursuant to Articles 35 to 50 shall apply only to those …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 19.07.2026Open original (EUR-Lex – consolidated version of 19.07.2026) ↗
  6. IVDR legacy devices of class B and sterile class A: formal application lodged with a notified body no later than · Art. 110(3c)(e)(iii) IVDRArticle 110 IVDR Transitional provisions1. From 26 May 2022, any publication of a notification in respect of a notified body in accordance with Directive 98/79/EC shall become void. 2. Certificates issued by notified bodies in accordance with Directive 98/79/EC prior to 25 May 2017 shall remain valid until the end of the period indicated on the certificate, except for certificates issued in accordance with Annex VI to Directive 98/79/EC which shall become …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 10.01.2025Open original (EUR-Lex – consolidated version of 10.01.2025) ↗
  7. IVDR legacy devices of class B and sterile class A: written agreement with the notified body no later than · Art. 110(3c)(f)(iii) IVDRArticle 110 IVDR Transitional provisions1. From 26 May 2022, any publication of a notification in respect of a notified body in accordance with Directive 98/79/EC shall become void. 2. Certificates issued by notified bodies in accordance with Directive 98/79/EC prior to 25 May 2017 shall remain valid until the end of the period indicated on the certificate, except for certificates issued in accordance with Annex VI to Directive 98/79/EC which shall become …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 10.01.2025Open original (EUR-Lex – consolidated version of 10.01.2025) ↗
  8. End of the MDR transitional period for class III and class IIb implantable devices (with exceptions), under the conditions of Art. 120(3c) · Art. 120(3a)(a) MDRArticle 120 MDR Transitional provisions1. From 26 May 2021 , any publication of a notification in respect of a notified body in accordance with Directives 90/385/EEC and 93/42/EEC shall become void. 2. Certificates issued by notified bodies in accordance with Directives 90/385/EEC and 93/42/EEC prior to 25 May 2017 shall remain valid until the end of the period indicated on the certificate, except for certificates issued in accordance with Annex 4 to …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 19.07.2026Open original (EUR-Lex – consolidated version of 19.07.2026) ↗
  9. End of the IVDR transitional period for devices with a certificate under Directive 98/79/EC and for class D, under the conditions of Art. 110(3c) · Art. 110(3a), (3b)(a) IVDRArticle 110 IVDR Transitional provisions1. From 26 May 2022, any publication of a notification in respect of a notified body in accordance with Directive 98/79/EC shall become void. 2. Certificates issued by notified bodies in accordance with Directive 98/79/EC prior to 25 May 2017 shall remain valid until the end of the period indicated on the certificate, except for certificates issued in accordance with Annex VI to Directive 98/79/EC which shall become …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 10.01.2025Open original (EUR-Lex – consolidated version of 10.01.2025) ↗
  10. End of the MDR transitional period for other class IIb, class IIa, class I sterile or with a measuring function, and for devices that require a notified body only under the MDR · Art. 120(3a)(b), (3b) MDRArticle 120 MDR Transitional provisions1. From 26 May 2021 , any publication of a notification in respect of a notified body in accordance with Directives 90/385/EEC and 93/42/EEC shall become void. 2. Certificates issued by notified bodies in accordance with Directives 90/385/EEC and 93/42/EEC prior to 25 May 2017 shall remain valid until the end of the period indicated on the certificate, except for certificates issued in accordance with Annex 4 to …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 19.07.2026Open original (EUR-Lex – consolidated version of 19.07.2026) ↗
  11. End of the IVDR transitional period for class C · Art. 110(3b)(b) IVDRArticle 110 IVDR Transitional provisions1. From 26 May 2022, any publication of a notification in respect of a notified body in accordance with Directive 98/79/EC shall become void. 2. Certificates issued by notified bodies in accordance with Directive 98/79/EC prior to 25 May 2017 shall remain valid until the end of the period indicated on the certificate, except for certificates issued in accordance with Annex VI to Directive 98/79/EC which shall become …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 10.01.2025Open original (EUR-Lex – consolidated version of 10.01.2025) ↗
  12. End of the IVDR transitional period for class B and sterile class A · Art. 110(3b)(c) IVDRArticle 110 IVDR Transitional provisions1. From 26 May 2022, any publication of a notification in respect of a notified body in accordance with Directive 98/79/EC shall become void. 2. Certificates issued by notified bodies in accordance with Directive 98/79/EC prior to 25 May 2017 shall remain valid until the end of the period indicated on the certificate, except for certificates issued in accordance with Annex VI to Directive 98/79/EC which shall become …As of: 05.10.2026 · Source: EUR-Lex – consolidated version of 10.01.2025Open original (EUR-Lex – consolidated version of 10.01.2025) ↗

Date of application and transitional periods according to the consolidated versions of the MDR and IVDR. A Commission proposal of 16.12.2025 (COM(2025) 1023) provides for additional reporting obligations for vulnerabilities; it has not yet been adopted.

How Complass helps

  • Seven phases across the life cycle

    Classification and role, secure development with risk management, minimum IT environment requirements, technical documentation, post-market surveillance and vigilance, plus a dedicated phase for suppliers.

  • Requirement catalogues

    Cyber requirements from the MDR and IVDR, measures according to MDCG 2019-16 and security activities in the life cycle with status and evidence, linkable with the CRA, IEC 62443 and ISO 27001.

  • Templates

    Including security plan, threat model, security risk management file, SBOM register, minimum IT environment requirements, coordinated disclosure policy, patch and update concept and security agreement with suppliers.

  • Vulnerabilities and incidents

    SBOM matching against known vulnerabilities, recording of incidents and an overview of reporting deadlines.

The phases in the module

  1. Qualification, role and demarcation
  2. Secure development across the lifecycle
  3. Minimum requirements for the IT environment and operator information
  4. Technical documentation and conformity assessment
  5. After placing on the market: surveillance, vulnerabilities, updates and vigilance
  6. Suppliers to the medical technology industry
  7. Implementation in Complass

Catalogue: MDR/IVDR requirements relevant to cybersecurity

Matching modules

Matching offers

The medical technology industry template preselects the framework for the MDR and IVDR and the building blocks you need for the threat model, vulnerabilities and suppliers.

available

Industry template: Medical technology

  • Cybersecurity for medical devices under the MDR and IVDR
  • Vulnerabilities and SBOM
  • Risk management
  • MITRE ATT&CK for the threat model
  • Supplier Management

from €476 per month plus VAT in the Start package, size S, annual payment

All prices are for businesses, not for consumers. They are net plus VAT with annual payment; monthly payment carries a surcharge of 15 %. As of 16 October 2026. Enterprise and groups of companies on request.

Frequently asked questions

We only supply electronics and firmware to medical device manufacturers. Does this concern us?

Indirectly, yes: your customers must demonstrate the MDR cyber requirements and expect information and commitments from you for this. If you also sell the component to other industries, the Cyber Resilience Act generally applies to it as well. The module contains a dedicated phase for suppliers.

Does the module replace our quality management system?

No. Complass structures the cyber requirements and evidence and can be integrated into your existing QMS; conformity assessment and approvals remain with you and your notified body.

Are standards such as IEC 81001-5-1 included?

The module describes the activities in its own words with references to the clauses. You obtain the standard text itself from a standards distributor; you can store excerpts from your licensed edition in the project.

Try Complass with your own data

Set up your trial yourself, with a sample project per framework if you like. If you would rather see Complass first, request a demo.